BASTIDE LE CONFORT MEDICAL (BLC.PA) Stock Fundamental Analysis
Europe - EPA:BLC - FR0000035370 - Common Stock
24.475 EUR
+0.38 (+1.56%)
Taking everything into account, BLC scores 4 out of 10 in our fundamental rating. BLC was compared to 27 industry peers in the Health Care Providers & Services industry. While BLC is still in line with the averages on profitability rating, there are concerns on its financial health. BLC has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year BLC was profitable.
BLC had a positive operating cash flow in the past year.
BLC had positive earnings in 4 of the past 5 years.
Each year in the past 5 years BLC had a positive operating cash flow.
1.2 Ratios
BLC has a Return On Assets of 0.25%. This is in the lower half of the industry: BLC underperforms 70.37% of its industry peers.
With a Return On Equity value of 2.25%, BLC is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
BLC's Return On Invested Capital of 5.67% is fine compared to the rest of the industry. BLC outperforms 62.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.25% | ||
| ROE | 2.25% | ||
| ROIC | 5.67% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BLC has a worse Profit Margin (0.36%) than 66.67% of its industry peers.
BLC's Profit Margin has declined in the last couple of years.
BLC has a better Operating Margin (7.87%) than 66.67% of its industry peers.
In the last couple of years the Operating Margin of BLC has remained more or less at the same level.
With a decent Gross Margin value of 67.54%, BLC is doing good in the industry, outperforming 74.07% of the companies in the same industry.
In the last couple of years the Gross Margin of BLC has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.87% | ||
| PM (TTM) | 0.36% | ||
| GM | 67.54% |
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BLC is destroying value.
BLC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
BLC has an Altman-Z score of 1.26. This is a bad value and indicates that BLC is not financially healthy and even has some risk of bankruptcy.
BLC has a worse Altman-Z score (1.26) than 66.67% of its industry peers.
BLC has a debt to FCF ratio of 9.33. This is a negative value and a sign of low solvency as BLC would need 9.33 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 9.33, BLC is in line with its industry, outperforming 48.15% of the companies in the same industry.
A Debt/Equity ratio of 5.20 is on the high side and indicates that BLC has dependencies on debt financing.
BLC has a Debt to Equity ratio of 5.20. This is amonst the worse of the industry: BLC underperforms 88.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.2 | ||
| Debt/FCF | 9.33 | ||
| Altman-Z | 1.26 |
ROIC/WACC0.98
WACC5.77%
2.3 Liquidity
A Current Ratio of 1.19 indicates that BLC should not have too much problems paying its short term obligations.
The Current ratio of BLC (1.19) is better than 62.96% of its industry peers.
BLC has a Quick Ratio of 1.19. This is a bad value and indicates that BLC is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.96, BLC is in line with its industry, outperforming 55.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.19 | ||
| Quick Ratio | 0.96 |
3. Growth
3.1 Past
BLC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 158.33%, which is quite impressive.
BLC shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -46.37% yearly.
Looking at the last year, BLC shows a small growth in Revenue. The Revenue has grown by 6.35% in the last year.
Measured over the past years, BLC shows a small growth in Revenue. The Revenue has been growing by 5.12% on average per year.
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
3.2 Future
Based on estimates for the next years, BLC will show a small growth in Earnings Per Share. The EPS will grow by 5.84% on average per year.
Based on estimates for the next years, BLC will show a small growth in Revenue. The Revenue will grow by 7.69% on average per year.
EPS Next Y24.04%
EPS Next 2Y5.84%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year1.83%
Revenue Next 2Y3.8%
Revenue Next 3Y9.77%
Revenue Next 5Y7.69%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 349.64, which means the current valuation is very expensive for BLC.
77.78% of the companies in the same industry are cheaper than BLC, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.13. BLC is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 9.39, which indicates a very decent valuation of BLC.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BLC indicates a rather cheap valuation: BLC is cheaper than 92.59% of the companies listed in the same industry.
BLC's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.35.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 349.64 | ||
| Fwd PE | 9.39 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BLC is valued cheaply inside the industry as 81.48% of the companies are valued more expensively.
85.19% of the companies in the same industry are more expensive than BLC, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4 | ||
| EV/EBITDA | 5.87 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BLC does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)14.55
PEG (5Y)N/A
EPS Next 2Y5.84%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for BLC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:BLC (11/5/2025, 5:24:44 PM)
24.475
+0.38 (+1.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.14%
Inst Owner ChangeN/A
Ins Owners1.58%
Ins Owner ChangeN/A
Market Cap180.38M
Revenue(TTM)491.18M
Net Income(TTM)1.71M
Analysts83.33
Price Target36.72 (50.03%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.22
Dividend Growth(5Y)-3.5%
DP42.86%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)9.09%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-23.78%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-17.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 349.64 | ||
| Fwd PE | 9.39 | ||
| P/S | 0.38 | ||
| P/FCF | 4 | ||
| P/OCF | 1.61 | ||
| P/B | 2.37 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.87 |
EPS(TTM)0.07
EY0.29%
EPS(NY)2.61
Fwd EY10.65%
FCF(TTM)6.12
FCFY25%
OCF(TTM)15.22
OCFY62.17%
SpS64.09
BVpS10.32
TBVpS-19.15
PEG (NY)14.55
PEG (5Y)N/A
Graham Number4.03
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.25% | ||
| ROE | 2.25% | ||
| ROCE | 7.72% | ||
| ROIC | 5.67% | ||
| ROICexc | 5.68% | ||
| ROICexgc | 10.34% | ||
| OM | 7.87% | ||
| PM (TTM) | 0.36% | ||
| GM | 67.54% | ||
| FCFM | 9.55% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
F-Score5
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.2 | ||
| Debt/FCF | 9.33 | ||
| Debt/EBITDA | 3.88 | ||
| Cap/Depr | 103.59% | ||
| Cap/Sales | 14.19% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 110.05% | ||
| Profit Quality | 2640.05% | ||
| Current Ratio | 1.19 | ||
| Quick Ratio | 0.96 | ||
| Altman-Z | 1.26 |
F-Score5
WACC5.77%
ROIC/WACC0.98
Cap/Depr(3y)92.61%
Cap/Depr(5y)91.81%
Cap/Sales(3y)11.59%
Cap/Sales(5y)11.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
EPS Next Y24.04%
EPS Next 2Y5.84%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
Revenue Next Year1.83%
Revenue Next 2Y3.8%
Revenue Next 3Y9.77%
Revenue Next 5Y7.69%
EBIT growth 1Y-6.92%
EBIT growth 3Y7.18%
EBIT growth 5Y5.9%
EBIT Next Year133.33%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y31.91%
FCF growth 3Y107.15%
FCF growth 5Y33.43%
OCF growth 1Y27.54%
OCF growth 3Y17.38%
OCF growth 5Y14.21%
BASTIDE LE CONFORT MEDICAL / BLC.PA FAQ
Can you provide the ChartMill fundamental rating for BASTIDE LE CONFORT MEDICAL?
ChartMill assigns a fundamental rating of 4 / 10 to BLC.PA.
What is the valuation status for BLC stock?
ChartMill assigns a valuation rating of 5 / 10 to BASTIDE LE CONFORT MEDICAL (BLC.PA). This can be considered as Fairly Valued.
Can you provide the profitability details for BASTIDE LE CONFORT MEDICAL?
BASTIDE LE CONFORT MEDICAL (BLC.PA) has a profitability rating of 4 / 10.
What is the valuation of BASTIDE LE CONFORT MEDICAL based on its PE and PB ratios?
The Price/Earnings (PE) ratio for BASTIDE LE CONFORT MEDICAL (BLC.PA) is 349.64 and the Price/Book (PB) ratio is 2.37.
How sustainable is the dividend of BASTIDE LE CONFORT MEDICAL (BLC.PA) stock?
The dividend rating of BASTIDE LE CONFORT MEDICAL (BLC.PA) is 0 / 10 and the dividend payout ratio is 42.86%.